Guan et al. (46) reported that high PD-L1 expression may contribute to the immunosuppressive role of CD24+CD38+CD19+ Bregs in invasive breast cancer and that PD-L1+CD24+CD38+CD19+ Bregs may serve as a target in immunotherapy. The gene discussed is CD274; the disease is invasive breast carcinoma.